Clinical trial
Detrol LA In Men With Overactive Bladder.
NCT00282932 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00282932 |
|---|---|
| Title | Detrol LA In Men With Overactive Bladder. |
| Official title | A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker. |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Overactive Bladder (OAB) |
| Intervention type | Drug |
| Interventions | Detrol LA |
| Enrollment | 600 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2007 |
| Completion | May 14, 2007 |
| First posted | Jan 27, 2006 |
| Last update posted | Jan 27, 2021 |
| Countries | Canada, Denmark, Germany, Italy, Mexico, Norway, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan and 3 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: